In this video, InMed Pharmaceuticals CEO Eric A. Adams speaks about the company’s ocular disease program. INM-088 is a cannabinol (CBN) formulation showing potential to reduce intraocular pressure and neuroprotection of the eye, important for glaucoma and several other eye diseases. InMed has conducted a number of preclinical studies of CBN, comparing it against several cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). CBN demonstrated the most optimal effect for glaucoma over other cannabinoids.
InMed presents Phase 2 clinical study results at 12th World Congress on Itch
At the 12th World Congress on Itch (WCI), held in Miami on November 5-7, 2023, InMed’s Senior VP, Clinical and Regulatory Affairs, Alexandra Mancini presented